AKRO News and Press, Akero Therapeutics Inc. From 10/09/23

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Tuesday, Octob...

As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsening of fibrosis Authors conclude robust data set indicates the potential of EFX to improv...

2023-09-19 15:40:37 ET More on Akero Therapeutics Seeking Alpha’s Quant Rating on Akero Therapeutics Historical earnings data for Akero Therapeutics Financial information for Akero Therapeutics Akero Therapeutics: An Assessment 89bio gains as U...

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will pr...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-28 12:36:36 ET More on Akero, 89bio, etc. Akero Therapeutics: An Assessment 89bio, Inc.: A Big Bet On NASH Akero Therapeutics: Marching On And Delivering Promising Results Akero gains 15% on potential of liver disease drug and weight loss therapy comb...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and da...

2023-08-24 07:41:04 ET Summary Akero Therapeutics is a biopharmaceutical company focused on developing therapies for nonalcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease that can lead to liver failure and other serious health complication...

2023-08-14 13:19:20 ET Despite recent setbacks, drugmakers are still forging ahead in their quest to develop effective treatments for non-alcoholic steatohepatitis, or NASH, a growing public health concern that could represent a roughly $108B global market opportunity by 2030. According...

2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...